VistaGen Therapeutics (NASDAQ: VTGN) reported Q1 EPS of ($0.94), $0.08 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $184.6 thousand.

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.